A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects

Trial Profile

A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Ibrutinib (Primary) ; Moxifloxacin
  • Indications B cell lymphoma; Breast cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Graft-versus-host disease; Hairy cell leukaemia; MALT lymphoma; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Jul 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
    • 03 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 25 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top